Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 04, 2018 ) Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
Market share of global Hemophilia A and B Recombinant Factor Replacement Therapy industry is dominate by companies like Pfizer, Novo Nordisk, Baxalta, Bayer, Biogen, Csl Behring, Emergent Biosolutions, Spark Therapeutics, Uniqure and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2016-2017).
Access Report Details at: https://www.themarketreports.com/report/global-hemophilia-a-and-b-recombinant-factor-replacement-therapy-market-2018-by-manufacturers-countries-type-and-application-forecast-to-2023
With the help of 15 chapters spread over 100 pages this report describe Hemophilia A and B Recombinant Factor Replacement Therapy Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Hemophilia A and B Recombinant Factor Replacement Therapy, in 2016 and 2017 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2017 to 2022 is provided in this research report. At last information about Hemophilia A and B Recombinant Factor Replacement Therapy sales channel, distributors, traders, dealers, and research findings completes the global Hemophilia A and B Recombinant Factor Replacement Therapy market research report.
Market Segment by Regions, regional analysis covers: • North America (USA, Canada and Mexico) • Europe (Germany, France, UK, Russia and Italy) • Asia-Pacific (China, Japan, Korea, India and Southeast Asia) • South America (Brazil, Argentina, Columbia, etc.) • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers: • Haemophilia A • Haemophilia B
Market Segment by Applications, can be divided into • Hospitals • Clinics • Ambulatory Surgical Centers
Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1323617
Table of Contents 1 Market Overview 2 Manufacturers Profiles 3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Competitions, by Manufacturer 4 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Analysis by Regions 5 North America Hemophilia A and B Recombinant Factor Replacement Therapy by Countries 6 Europe Hemophilia A and B Recombinant Factor Replacement Therapy by Countries 7 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy by Countries 8 South America Hemophilia A and B Recombinant Factor Replacement Therapy by Countries 9 Middle East and Africa Hemophilia A and B Recombinant Factor Replacement Therapy by Countries 10 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment by Type 11 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment by Application 12 Hemophilia A and B Recombinant Factor Replacement Therapy Market Forecast (2018-2023) 13 Sales Channel, Distributors, Traders and Dealers 14 Research Findings and Conclusion 15 Appendix
Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1323617
The Market Reports
Shirish Gupta
+16314071315
web@themarketreports.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|